Ventripoint Announces Extension and Up Size of Non-Brokered Convertible Debenture Unit Private Placement

Executive Summary

• Ventripoint Diagnostics seeks TSX Venture Exchange approval to extend its non‑brokered private placement of unsecured convertible debentures to November 2, 2025.
• The company requests permission to increase the offering size from $500,000 to $560,000.
• Proceeds will fund sales & marketing, key personnel hires, and general working capital.

Key Details

• Offering Structure: Each unit consists of one (1) unsecured convertible debenture ($1,000 principal) plus 9,000 common‑share purchase warrants.
• Conversion Terms: Debentures convertible at any time before maturity (Dec 31 2027) at $0.11 per Common Share.
• Warrant Exercise Price: $0.14 per share, exercisable until Dec 31 2027.
• Interest Rate: 10% per annum, payable semi‑annually in cash or by issuance of Common Shares at a 20‑day VWAP market price (subject to Exchange approval).
• Maturity Date: December 31 2027.
• Use of Proceeds: Allocate funds to operational costs related to sales and marketing, addition of key personnel, and general working capital.
• Holding Period: Securities subject to a lock‑up of four months plus one day from the closing date.
• Regulatory Note: Offering not registered under U.S. securities laws; cannot be offered or sold in the United States absent registration or exemption.

Notable Quotes

(No executive quotes provided in the release.)